206results about How to "The source is easy to get" patented technology

The invention provides an efficient low-phosphorus compound water treatment agent and belongs to the technical field of industrial circulating cooling water treatment. The water treatment agent consists of the following raw materials: polyaspartic acid (PESA), 2-phosphonobutane-1,2,4-tricarboxylic acid (PBTCA), zinc salt, azoles, maleic acid-acrylic copolymer (MA / AA) and deionized water, wherein PESA is taken as a main scale inhibitor, PBTCA and MA / AA are taken as auxiliary scale inhibitors, a corrosion inhibitor is formed by the zinc salt, the azoles, PBTCA and PESA, and MA / AA is taken as a dispersing agent. By fully utilizing the synergistic effect of various components, a multifunctional low-phosphorus compound water treatment agent with scale and corrosion inhibition functions is formed.

The invention relates to the use of acetamide dehydrogenation silibinin as a medicament for treating viral hepatitis B, in particular to the use of dehydrogenation silibinin esters flavonoid lignanoid replaced by A ring methoxy formyl amine or pharmaceutically acceptable salt as the medicament for eliminating HBsAg (hepatitis B surface antigen) and HBeAg (hepatitis Be antigen) and restraining copy of HBV DNA. The cetamide dehydrogenation silibinin can obviously restrain the HBsAg and HBeAg activity, and the strengths for eliminating the HBsAg and HBeAg are 90.5% and 63.6% at the concentration of 20 microgramme / milliter and are 5.6 times and 3.8 times more than positive contrast medicament alpha-interferon. Meanwhile, the restraining rate to the HBV DNA is 90.4% at the concentration, is 12% higher than lamivudine, and is 2.4 times more than a- interferon. Therefore, the flavonoid lignanoid or the pharmaceutically acceptable salt can be expected for treating hepatitis B virus infection as the non-nucleoside medicament.

The invention relates to the application of flavonoid quercetin dimmer as the medicament for treating viral hepatitis B, in particular to the application of flavonoid quercetin dimmer or pharmaceutically acceptable salt thereof to the preparation of the medicament for eliminating HBsAg and HBeAg and inhibiting HBV DNA replication. The flavonoid quercetin dimmer or pharmaceutically acceptable salt thereof has obvious HBsAg and HBeAg inhibiting activity, and at the concentration of 100mcg / ml, the flavonoid quercetin dimmer pharmaceutically acceptable salt thereof has the HBsAg eliminating strength of 65.7% and the HBeAg eliminating strength of 44.8% which are respectively 4.1 times and 2.7 times higher than the positive control medicament of Alpha-interferon and has the HBV DNA inhibiting ratio of 44.8% which is 117% of the HBV DNA inhibiting ratio of the Alpha-interferon at the highest test concentration. Therefore, the flavonoid quercetin dimmer or pharmaceutically acceptable salt thereof can be expectedly used for preparing the non-nucleoside medicament for eliminating HBsAg and HBeAg, inhibiting HBV DNA replication and treating viral hepatitis B.

The invention relates to application of ring E bromine substituted silybin in preparing medicaments for treating viral hepatitis B, in particular to application of a compound of a formula (1) and a pharmaceutically acceptable salt thereof in preparing medicaments for clearing away hepatitis B surface antigens (HBsAg) and hepatitis e antigens (HBeAg) and suppressing the HBV (Hepatitis B Virus) DNA replication. The compound has definite activity on suppressing the HBsAg and the HBeAg, and in the presence of a concentration of 100 micrograms / milliliter, the intensities of the compound for clearing away the HBsAg and the HBeAg are respectively 38.2 percent and 39.1 percent which are respectively 2.4 times and 2.3 times of that of a positive control medicament (10,000 units / milliliter of alpha-interferon). Meanwhile, in the presence of the concentration, the suppression ratio of the compound on the HBV DNA is 36 percent which is close to that of the alpha-interferon. Accordingly, the flavone lignan or the pharmaceutically acceptable salt thereof are indicated to be capable of being used for preparing non-nucleoside medicaments for clearing away the HBsAg and the HBeAg, suppressing the HBV DNA replication and treating HBV infection diseases.

The invention relates to application of ring A coupling flavonolignan in preparing medicaments for treating viral hepatitis B, in particular to application of a compound of the formula (1) or a pharmaceutically acceptable salt thereof in preparing medicaments for clearing away HBsAg (Hepatitis B Surface Antigen) and HBeAg (Hepatitis B e Antigen) and suppressing the HBV (Hepatitis B Virus) DNA replication. The intensities of the flavonolignan for clearing away the HBsAg and the HBeAg are respectively 29.4 percent and 29.1 percent in the presence of a concentration of 20 micrograms / milliliter, which is respectively 1.8 times and 1.7 times of the corresponding activity of a positive control medicament (10,000 units / milliliter of alpha-interferon). What is even more exciting is that in the presence of the concentration, the suppression rate of the flavonolignan to the HBV DNA is higher than 83 percent, which is higher than that of Lamivudine which is a positive control and is 2.2 times of that of the alpha-interferon to the HBV DNA. Accordingly, the flavonolignan and the pharmaceutically acceptable salt thereof are indicated to be capable of being expected to be used for preparing non-nucleoside medicaments for clearing away the HBsAg and the HBeAg, suppressing the HBV DNA replication and treating HBV infection diseases.

The invention relates to application of substituted isosilybin in preparing a medicament for treating virus hepatitis B, in particular to application of E-ring substituted isosilybin or medicinal salt thereof in preparing a medicament for clearing hepatitis B e antigen, inhibiting HBV DNA replication and treating hepatitis B virus infected diseases. The E-ring substituted isosilybin has strong effect of inhibiting HBeAg activity, and the strength of the E-ring substituted isosilybin at the concentration of 100 micrograms per milliliter for clearing the HBeAg is 3.5 times that of a positive control front-line medicament (10,000 units per milliliter of alpha-interferon); and moreover, the compound at the concentration of 100 micrograms per milliliter has strong inhibiting rate (97.7 percent) on the HBV DNA. Pharmacodynamical results show that the E-ring substituted isosilybin or the medicinal salt thereof can be expected to be used for preparing the medicament for treating the hepatitis B virus infected diseases.

The invention relates to application of flavone lignan (+ / -) Scutellaprostin A in preparing medicaments for treating viral hepatitis type B, in particular to a compound with the formula (1) or pharmaceutically-acceptable salts thereof for preparing medicaments for clearing HBsAg and HBeAg and suppressing HBV (Hepatitis B Virus) DNA replication. In the invention, the intensities of the compound for clearing the HBsAg and the HBeAg under the concentration of 20 micrograms / milliliter respectively reach 81.8 percent and 81.9 percent, which are respectively 5.1 times and 4.8 times as high as the corresponding activity of alpha-interferon used as a positive contrast medicament; and what is more exciting, when the compound has the concentration, the compound performs a suppression ratio higher than 81 percent, and the value is also higher than that of both lamivudine and alpha-interferon. Accordingly, the flavone lignan or the pharmaceutically-acceptable salts can be expectably used for preparing nucleoside medicaments for clearing the HBsAg and the HBeAg, suppressing the HBV DNA replication and treating HBV infected diseases.

The invention relates to application of an angle flavonoids lignan to preparation of medicaments for treating viral hepatitis B, in particular to application of the angle flavonoids lignan or medicinal salts thereof to preparation of medicaments for inhibiting hepatisis B virus (HBV) DNA replication and treating HBV infection diseases. The flavonoids lignan can exactly inhibit HBV DNA activity; the inhibition activity of the flavonoids lignan with high dosage (20 microgram / ml) to the HBV DNA replication is 189 percent higher than that of alpha-interferon with the maximum concentration of 10,000 unit / ml; and the flavonoids lignan belongs to a strong-effect non-nucleosides inhibition HBV natural product. The pharmacological results show that the angle flavonoids lignan or the medicinal salts thereof can be expected to be used for preparing the medicaments for inhibiting hepatisis B virus (HBV) DNA replication and treating the HBV infection diseases.

The invention relates to application of ring A dioxane flavonolignan in preparing medicaments for resisting hepatitis B viruses (HBV), in particular to application of ring A dioxane coupling type flavone lignan or a pharmaceutically acceptable salt thereof in preparing medicaments for clearing away hepatitis B e antigen (HBeAg), suppressing the HBV DNA replication and treating HBV infection diseases. The flavonolignan has certain activity on resisting the HBeAg, and the intensity of the flavonolignan for clearing away the HBeAg is higher than that of Lamivudine which is a positive control and close to that of 10,000 units / milliliter of alpha-interferon. Meanwhile, the suppression ratio of the compound to the HBV DNA replication is higher than 80 percent in the presence of a concentration of 100 micrograms / milliliter. The pharmacodynamical results indicate that the flavonolignan or the pharmaceutically acceptable salt thereof can be expected to be used for preparing the medicaments for clearing away the HBeAg, suppressing the HBV DNA replication and treating the HBV infection diseases.

The invention relates to application of E-ring demethoxy-silibinin for preparing medicaments for treating viral hepatitis B, and particularly to application of compound in formula (1) and pharmaceutically acceptable salt thereof for preparing medicaments for clearing HBsAg and HBeAg and suppressing HBV DNA replication. The invention has extremely superactive activity for suppressing the HBsAg and HBeAg; in the presence of the concentration of 20 microgram per millilitre, the intensities for clearing the HBsAg and HBeAg are 95.0% and 34.4% respectively, which are 5.9 and 2.0 times corresponding activity of a positive control medicament alpha-interferon; and it should be noticed that the suppression ratio of the medicament for HBV DNA at the concentration is about 91.5%, which is 13% higher than lamivudine and 2.4 times alpha-interferon suppression activity. In summary, the flavonolignans or pharmaceutically acceptable salt thereof can be prospectively used for preparing non-nucleoside medicaments for clearing the HBsAg and HBeAg, suppressing HBV DNA replication and treating hepatitis B virus infection disease.

The invention relates to application of diallyl propyl flavonolignan in preparation a medicament for curing hepatitis B, in particular to application of a flavonolignan or pharmaceutically acceptable salts thereof in preparation of the medicament for curing the hepatitis B by clearing hepatitis B e-antigen and inhibiting HBV DNA replication. The flavonolignan has hepatitis B virus e-antigen (HBeAg) inhibiting activities, and has the inhibition strength higher than a positive control first-line medicament, namely lamivudine and alpha-interferon, at a low concentration of 20 mu g / ml; simultaneously, at the concentration of 5 mu g / ml, the compound has an inhibition rate of the HBV DNA of over 70 percent; and therefore, the flavonolignan can be expected for preparing the medicament for curing the hepatitis B virus infection diseases by clearing the hepatitis B e-antigen and inhibiting the HBV DNA replication.

The invention relates to application of ring A substituted silybin ester in preparing medicaments for treating viral hepatitis B, in particular to application of silybin ester flavonolignan substituted by ethoxycarbonyl methyl on the ring A or a pharmaceutically acceptable salt thereof for preparing medicaments for reducing the hepatitis B virus surface antigen (HBsAg), suppressing the HBV (Hepatitis B Virus) DNA replication and treating HBV infection diseases. The flavonolignan has quite obvious activity on suppressing the HBsAg, and in the presence of a concentration of 100 micrograms / milliliter, the intensity of the flavonolignan for clearing away the HBsAG exceeds that of alpha-interferon which is a positive control medicament by 3.3 times. Meanwhile, in the presence of a concentration of 20 micrograms / milliliter, suppression ratio of the compound to the HBV DNA is close to 60 percent. The pharmacodynamical results indicate that the flavonolignan or the pharmaceutically acceptable salt thereof can be expected to be used for preparing the medicaments for treating the HBV infection diseases.

The invention relates to application of dimethyl dehydrated silybin in preparing medicaments for treating virus hepatitis B, in particular to the application of 7 and 20-position methyl substituted dehydrated silybin or pharmaceutically acceptable salts thereof in preparing medicaments for removing HBsAG and HBsAg and medicaments for inhibiting HBV DNA replication. The dehydrated silybin has remarkably HBsAg and HBeAg inhibiting activity, wherein the strength for removing the HBsAg and the HBeAg at the concentration of 20 milligram / milliliter is 88.9 percent and 84.1 percent respectively, which are 5.5 times and 5.0 times that of a positive contrast medicament. More importantly, the dehydrated silybin shows the HBV DNA inhibition ratio of about 99.6 percent at the concentration of 20 milligram / milliliter, the activity exceeds lamivudine by 23 percent, which is 2.6 times that of interferon. Therefore, favonolignan or pharmaceutically acceptable salts thereof can be predictably used for preparing the non-nucleoside reverse transcriptase inhibitor medicaments for removing the HBsAg and HBeAg, inhibiting HBV DNA replication and treating hepatitis B virus infection diseases.

The invention provides a coumarin dyestuff linked by naphthene ketones, method for synthesis and use, wherein the method employs the conventional hydroxyaldehyde condensation reaction and consists of, charging naphthene ketone, corresponding aldehydes with A1 groups into reactor, obtaining semi-naphthene ketone dyestuff with A1 groups, subjecting corresponding third position methyl substituted or fourth position methyl substituted coumarin having A2 group and selenious acid in another catalyst case to obtain coumarin aldehyde having A2 group, subjecting the A1 group semi-naphthene ketone dyestuff and A2 group coumarin aldehydes to reaction at the presence of mixed solvent of dimethylbenzene and alcohol, thus obtaining coumarin type dyestuffs coupled by naphthene ketones.

The present invention relates to preparation of a blattodea polypeptide, and uses of the blattodea polypeptide in anti-gram-positive bacteria and anti-gram-negative bacteria. Specifically the present invention relates to a blattodea extract effective fraction having a function of prevention and treatment of bacterial infection diseases, a preparation method and a medical use thereof. The Periplaneta Americana extract effective fraction of the present invention is a polypeptide substance with a molecular weight less than 5000 dalton, and is prepared by the following steps: carrying out solvent extraction and membrane separation on fresh polypide or dried polypide of Periplaneta Americana to obtain the product of the present invention, wherein the polypeptide active substance of the effective fraction has significant anti-gram-positive bacteria activity and anti-gram-negative bacteria activity, can be prepared into forms of a hydrogel, a cataplasm, lyophilized powder, a water agent, an aerosol, a suppository, a film agent, an external application liniment, and an ointment, and can be used for preparations of drugs for prevention and treatment of diseases related to gram-positive bacteria and gram-negative bacteria and infections, daily chemical products or medical devices.

The invention relates to two photon polymerization initiating system, especially relates to a high- effective method for synthesizing coumarins dyestuff connected with stilbene and its application in two photon polymerization. It comprises following steps: dissolving the mediate coumarins dyestuff with A1 gene into organic solvent; adding alkaline catalyst solution into it; dropping the organic phosphonic solvent carrying A2 gene with the same molar weight to that of coumarins dyestuff into reation system, heating to solvent boiling and refluxing; cooling and separting organic phase from water phase through extraction with organic solvent; drying and evaporating organic phase, separating coarse product with column chromatography, heating with iodine with its amount the same to that of catalyst, getting coumarins dyestuff connected with stilbene, which is used as photosensitiser in photon polymerization, and its structure is as follows: the substituents of A1 and A2 are the same or different, and are chose from alkyl, alkoxy, amido, heterocycle or substituted phenyl.

The invention provides a compound simulating cabin for rat and mice tests. The compound simulating cabin is characterized by comprising a test cabin body, a nitrogen input device, an oxygen input device, a carbon dioxide input device, a concentration and humidity detecting device, a one-way valve, a mixing fan, a PLC and a host computer, wherein force control configuration software is installed on the host computer; outputs of the nitrogen input device, the oxygen input device and the carbon dioxide input device are all connected with the test cabin body; gases in a certain proportion are introduced into the test cabin body by the nitrogen input device, the oxygen input device and the carbon dioxide input device according to a preset environmental model requirement; the numerical values of the gases in the test cabin body are monitored in real time by the concentration and humidity detecting device; and a preset program of the host computer is used for controlling, thereby controlling the switch-on / off of the nitrogen input device, the oxygen input device and the carbon dioxide input device.

The invention relates to a process for synthesizing 3- or 4- carbonyl substituted coumarin connected by naphthenones and its use. The preparation process using general aldol condensation reaction comprises cyclanone and its corresponding aldehyde compounds with A1 group are added in reactor to produce semi-cyclanone with A1 group; 3- or 4- acetyl substituted coumarin with A2 group and selenious acid are added in another reactor to produce coumarin aldehyde with A2 group; said semi-cyclanone with A1 group dye reacts with coumarin aldehyde with A2 group in the presence of xylene and ethanol mixed solvent to form 3- or 4- carbonyl substituted coumarin connected by naphthenones. The product can be used for visible light polymerization of olefine monomer in photosensitized initiation system and used as photo curing materials, etc.

The invention belongs to a novel environment friendly water treatment agent, in particular to a phosphorus-free composite water treatment agent, comprising the following components in parts by weight: 1-7 parts of polyaspartic acid, 0.5-5 parts of molybdate, 1-10 parts of polyacrylic acid, 1-10 parts of terpolymer and 2-100 parts of bactericide. The water treatment agent does not contain phosphorus and other hazardous substance which are harmful to the environment, can not easily cause eutrophication, can prevent the pollution of the 'red tide' from being generated in the peripheral water area, has good corrosion inhibition and scale inhibition effects and takes the common surface water as make-up water, when the cycle of concentration is 2-6, the annual corrosion inhibition of carbon steel reaches lower than 0.02mm / a, and the scale inhibition of the calcium carbonate in the water can reach more than 90 percent. The invention is used for the water treatment of industrial recirculating water cooling systems and boiler water systems.

The invention discloses a catalyzing and synthesizing liquid injecting fuel method with cyclopentadiene and bridge dicyclopentadiene relating to an injecting fuel preparing technique, which comprises the following steps: regarding the mixture of cyclopentadiene and bridge dicyclopentadiene as the material; adding ZSM, Y, mordenite or beta molecular sieve accelerant; proceeding the polymerization reaction at 160Deg. C -250Deg. C, 0. 1MPa -3MPa; distilling at 130Deg. C -160Deg. C in order to remove no reaction materials; adding Pd / gamma-Al2O3, Pd / SiO2 or palladium carbon hydrogenation accelerant to the polymer; getting the liquid injecting fuel with at hydrogenation the hydrogen gas pressure of 0. 5-5MPa, 140-80Deg. C. The invention provides a big density, a low freezing point, which provides a simple technique.

The invention discloses a method for preparing a desulfurizing agent by carrying out thermal activation on red mud and active carbon and belongs to the field of coal desulfurization. The method comprises the specific steps: step a: sieving the red mud and the active carbon with a 300-mesh sieve respectively; drying at 105 DEG C until the weight is constant; step b: mixing the red mud and the active carbon according to the mass ratio ranging from (1 to 10) to (1 to 30); step c: activating a mixture in the step b in a muffle furnace at 700 DEG C to 1100 DEG C for 10min to 30min; after finishing the thermal activation, naturally cooling to room temperature under a sealed condition. The method disclosed by the invention has the advantages that the waste dreg red mud produced in a production process of aluminum oxide is prepared into the desulfurizing agent; a preparation process is simple and the activation time is short; the wet-method desulfurizing efficiency can reach 90 percent; the desulfurizing rate can be maintained to be 87 percent when the desulfurizing agent is continuously used under a low pH (Potential of Hydrogen) condition; the dosage of the desulfurizing agent is reduced so that the desulfurizing agent is economical and feasible.

The invention discloses lipstick containing Chinese herb extracts. The lipstick is prepared from 10-20 parts of candelilla wax, 10-20 parts of rose wax, 25-45 parts of olive oil, 20-30 parts of sweet almond oil, 15-30 parts of rose hip oil, 6-10 parts of Basella rubra, 1-5 parts of geranium essential oil, 3-8 parts of barbed skullcap herb extracts and 2-6 parts of chrysanthemum extracts. The lipstick has the efficacy of treating skin sensitivity of lips. The lipstick is prepared from pure natural materials, is safe and non-irritant and has the efficacy of treating sensitive lip skin after being used for a long time.

The invention relates to synthesis and application of o-hydroxy-containing Schiff base type visible light photosensitizer with a conjugated structure. A photosensitizer plays important roles of absorbing light and performing light action. The peak value of UV-visible absorption reaches over 390 nm, the half-peak width is about 100 nm, so that the visible light photosensitizer completely meets the requirement of visible light absorption and can be used for visible light polymerization. A general formula of a chemical structure of the visible light photosensitizer is shown as right, wherein compounds in the molecular structural formula (I) representA:R1, R3:H, R2:OCH3, OCH2CH3, OCH2CH2CH3, OCH2CH2CH2CH3, N(CH3)2, N(CH2CH3)2, N(CH2CH2CH3)2, N(CH2CH2CH2CH3)2, N(Ph)2; B:(R1:H, OCH3, R2,R3:OCH3). The o-hydroxy-containing Schiff base type visible light photosensitizer with the conjugated structure is performed chemical modification to ensure that the peak value of the UV-visible absorption shifts to over 390 nm; and the o-hydroxy-containing Schiff base type visible light photosensitizer with the conjugated structure can be used as a visible light photosensitizer to form a photosensitive system used for visible light polymerization of vinyl monomers in solution with an ultraviolet initiator and other auxiliary agents, or can be used for a photocuring material.

The invention relates to a periplaneta americana immunomodulating peptide and a preparation method and medical application thereof. Specifically, the invention relates to an immunomodulating peptide which is extracted from periplaneta americana and has the effects of preventing and treating tumor diseases and improving the immunity function of an organism. The polypeptide substance is a single chain polypeptide of which the amino acid sequence is arginine-arginine-asparagine-leucine-leucine-alanine-alanine-serine-leucine-leucine-asparagine- aspartate, and is prepared by extracting fresh or dry periplaneta americana in water or an organic solvent and a buffer solution and refining through a membrane separation method and an HPLC (High Performance Liquid Chromatography) technology. The immunomodulating peptide has remarkable antitumor activity and immunomodulating effect, and can be used to make medicaments for preventing and treating tumor diseases and / or modulating immunity, daily chemical products or medical devices.

The invention discloses a method for preparing porous nano ferroferric oxide. The method comprises the steps: dissolving two of FeCl2.4H2O, FeSO4.7H2O, FeCl3.6H2O and Fe2(SO4)3 in one of polyvinyl alcohol, ethanol and deionized water or a mixture thereof to obtain a mixed solution containing Fe<2+> and Fe<3+>; adding one of NaHCO3, N2H4.H2O, Na2CO3, (NH4)2CO3 and NH4HCO3 in one of polyvinyl alcohol, ethanol and deionized water or the mixture thereof to obtain an alkaline substance aqueous solution; mixing the mixed solution containing Fe<2+> and Fe<3+> with the alkaline substance aqueous solution in a reaction vessel, heating, and stirring; adjusting the pH of the stirred mixed liquid to 8-13, keeping for 0.5-3 h, gradually adjusting the temperature to 30-60 DEG C, keeping the constant temperature for 2-24 h, allowing the mixed liquid to fully undergo a reaction, and after finishing the reaction, cooling to the room temperature; and washing the precipitate product after reaction with one of anhydrous ethanol and deionized water or a mixture thereof until the pH is 7, and drying for 8-36 h. The reaction process has no need of inert gas protection, and the industrialized production doorsill is low.

The invention discloses a preparation method of a graphene / activated carbon microsphere. The graphene / activated carbon microsphere prepared by the method has the characteristics of spherical structure, large specific surface area and good dispersion, and effectively improves the electrochemical performance of cathode materials. The preparation method of the graphene / activated carbon microsphere includes ultrasonic dispersion, atomization pyrolysis, atomization drying and carbonization, integrates the whole production process, effectively controls the molding of the graphene / activated carbon microsphere, and ensures the material quality. The preparation method has the advantages of simple operation, low cost, energy saving and environmental protection. The prepared graphene / activated carbonmicrosphere has a large specific surface area, not only can be used for electrode materials, and also can be applied to catalyst carriers, water treatment, sewage purification, solvent adsorption andrecovery and other related fields, and has great application prospects.

The invention relates to a special fertilizer for cold water paddy rice, and a preparation and application method thereof. Raw materials of the special fertilizer comprise, by weight, 20 to 25 parts of urea, 10 to 20 parts of diammonium phosphate, 20 to 25 parts of potassium chloride, 15 to 20 parts of calcium magnesium phosphor, 10 to 15 parts of zinc sulfate and 10 to 20 parts of weathered coal. The special fertilizer for cold water paddy rice provided in the invention is developed and prepared by composite granulation on basis of characteristics of soil constraints of cold water fields, pattern of nutrient demands of crops and suitability among fertilizer varieties. According to the invention, the preparation method is simple, and the prepared fertilizer has lasting fertility and can effectively overcome soil constraints of cold water fields.

An asymmetric compound taking triphenylamine as nucleus and containing benzophenone fragment and a synthesis and an application thereof, belonging to the field of organic dye, in particular relating to the application of the asymmetric compound taking triphenylamine as nucleus and containing benzophenone fragment in photopolymerization. The general formula of the typical chemical structure is shown in formula (I), wherein compound in molecular structural formula (I) represents A: R1, R2: H, R3: CH3, OCH3, OCH2CH3, OCH2CH2CH3, OCH2CH2CH2CH3, N(CH3)2, N(CH2CH3)2, N(CH2CH2CH3)2, N(CH2CH2CH2CH3)2, CN, F, NO2; B: (R1, R2,:, R3: OCH3). 4-diethyl benzophenone phosphonate and derivative containing 4-aldehydegroup-triphenylamine compound react in a glass vessel under the alkaline condition to prepare the asymmetric non-conjugated compound taking triphenylamine as nucleus and containing benzophenone fragment, the absorption maximum thereof is at visible region, the organic dye can be used as light trigger to form a photosensitive system together with auxiliary agent trolamine to be used for visible light polymerization of alkene monomer in solution or to be used as photocuring material.

The invention relates to synthesis and application of p-methoxyl-containing Schiff base type visible light photosensitizer with a conjugated structure. A photosensitizer plays important roles of absorbing light and performing light action. The peak value of UV-visible absorption reaches over 380 nm, the half-peak width is about 100 nm, so that the visible light photosensitizer completely meets the requirement of visible light absorption and can be used for visible light polymerization. A general formula of a chemical structure of the visible light photosensitizer is shown as right, wherein compounds in the molecular structural formula (I) represent A:R1, R3:H, R2:OCH3, OCH2CH3, OCH2CH2CH3, OCH2CH2CH2CH3, N(CH3)2, N(CH2CH3)2, N(CH2CH2CH3)2, N(CH2CH2CH2CH3)2, N(Ph)2; B:(R1:H, OCH3, R2, R3:OCH3). The p-methoxyl-containing Schiff base type visible light photosensitizer with the conjugated structure is performed chemical modification to ensure that the peak value of the UV-visible absorption shifts to over 380 nm; and the p-methoxyl-containing Schiff base type visible light photosensitizer with the conjugated structure can be used as a visible light photosensitizer to form a photosensitive system used for visible light polymerization of vinyl monomers in solution with an ultraviolet initiator and other auxiliary agents, or can be used for a photocuring material.